$4.11
-0.20-4.64%
Last update: Oct 30, 4:00 PM
Atea Pharmaceuticals Inc (AVIR) Stock Price, Quote, News & History
AVIRNASDAQ
Atea Pharmaceuticals announced positive Phase 3 C-BEYOND trial results for its oral hepatitis C combination therapy vs. Gilead's therapy.
You can purchase shares of Atea Pharmaceuticals (NASDAQ:AVIR) through any online brokerage.
Other companies in Atea Pharmaceuticals’s space includes: Eli Lilly and Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co Inc (NYSE:MRK), Novartis AG (NYSE:NVS) and AstraZeneca PLC (NYSE:AZN).
Atea Pharmaceuticals has a consensus price target of $8.50.
The stock price for Atea Pharmaceuticals (NASDAQ: AVIR) is $4.11 last updated October 30, 2026 at 4:00 PM EDT.
There are no upcoming dividends for Atea Pharmaceuticals.
Atea Pharmaceuticals does not have any upcoming earnings scheduled.
There is no upcoming split for Atea Pharmaceuticals.
Atea Pharmaceuticals is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of...
